In situations where treatment with metreleptin is not possible (e.g., unavailable in the country, contraindicated), glucose-lowering agents such as sodium-glucose cotransporter-2 (SGLT2) inhibitors or glucagon-like peptide-1 receptor agonists (GLP-1 RAs), may help improve glycemic control in patients with partial lipodystrophy (71–73). The gene discussed is GLP1R; the disease is partial lipodystrophy.